--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About ABVX20260410C105
Biological Technology
Abivax Sa was incorporated on December 4, 2013 under the laws of France. The company is a clinical-stage biotechnology company focused on developing therapies that leverage the body's natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. Its lead drug candidate, obefazimod, is in Phase 3 development for the treatment of ulcerative colitis and is being developed for Crohn's disease.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
